Loss Widens 55% to $5.93m as Rhythm Biosciences Launches ColoSTAT® and geneType™

Transition from Development to Commercialisation

Rhythm Biosciences Limited (ASX:RHY) took a significant step forward in FY2026, moving from a development-stage company into a commercial diagnostics player. The company recorded its first commercial sales of both ColoSTAT®, a blood test for colorectal cancer detection, and geneType™, its genetic risk assessment platform. These milestones validate Rhythm’s end-to-end commercial infrastructure, including laboratory accreditation, manufacturing, and distribution arrangements, positioning it for scale.

ColoSTAT® received updated ISO 15189:2022 laboratory accreditation in December 2025 and NATA accreditation in March 2026, enabling clinical testing services to expand. Meanwhile, the geneType™ portfolio secured its first clinical sale in Southeast Asia and strengthened US partnerships, notably with Cancer IQ.

Market Access and Manufacturing Progress

Rhythm expanded its market footprint through a services agreement with 4Cyte Pathology, establishing a network of patient collection sites across eastern Australia. The ColoSTAT® Access Program attracted physician participants steadily throughout the year, underpinning real-world clinical adoption. On the manufacturing front, a commercial agreement secured scaled production of ColoSTAT® test kits ahead of anticipated volume growth, addressing a critical supply chain component.

Regulatory and International Evaluation Milestones

Independent peer-reviewed publication of ColoSTAT® clinical performance data provided external validation of the test’s efficacy. Importantly, the National Health Service (NHS) in England commenced an evaluation of ColoSTAT® within its bowel cancer screening pathway; a notable international endorsement that could open significant market opportunities. This evaluation marks a key regulatory and commercial inflection point for Rhythm’s global ambitions.

Financial Performance and Capital Position

Despite these operational advances, Rhythm’s financial results reflect the costs of scaling. The consolidated entity reported a loss after tax of $5.93 million for FY2026, up 55% from $3.83 million the prior year. This increase was driven primarily by higher personnel and commercialisation expenses as the company ramped up activities.

Revenue remained modest at $85,339, reflecting the nascent stage of commercial sales. Cash reserves improved to $3.36 million at year-end, bolstered by capital raises totaling over $9 million and expected R&D tax refunds. Operating cash outflows widened to $5.23 million, underscoring the ongoing investment required to transition to a revenue-generating business.

Governance and Leadership Changes

The company saw a key leadership change with Mr Gavin Fox-Smith appointed as Non-Executive Chairman in November 2025 following the resignation of Mr Otto Buttula. The board also announced the appointment of two new Non-Executive Directors, Ms Maureen Baker and Mr Carl Stubbings, effective August 2026, signaling a strengthening of governance as Rhythm scales.

Outlook and Risks

Rhythm enters FY2027 with both ColoSTAT® and geneType™ commercially available and a growing clinical footprint. The company’s stated focus is on converting physician interest into sustained test volumes while managing cash flow prudently. Directors express confidence in the company’s ability to raise further capital if required, supported by a successful track record.

However, the auditor’s report highlights a material uncertainty regarding going concern due to operating losses and cash burn. Rhythm acknowledges inherent risks including technology adoption, competitive pressures, regulatory hurdles, and reliance on commercial partnerships. The company’s ability to scale sales and secure reimbursement will be critical to its financial sustainability.

Investors should watch closely for quarterly sales updates, progress in the NHS evaluation, and capital raising activities as Rhythm navigates this pivotal growth phase.